AACR 2022 Sirpiglenastat (DRP-104), a novel broad acting glutamine antagonist, has therapeutic potential in targeting KEAP1-mutant lung cancer Thales Papagiannakopoulos Download Festival of Biologics USA, World Immunotherapy 2022 Sirpiglenastat (DRP-104), a broad acting glutamine antagonist, metabolically reprograms glutamine addicted cancer cells and significantly remodels the tumor microenvironment leading to anti-tumor immune responses Download  

Leave a Reply